Background/Aims: Mesenchymal stem cells (MSCs) do not readily migrate to appropriate sites, and this creates a major obstacle for their use in the treatment of graft-versus-host disease (GVHD). Intercellular adhesion molecule-1 (ICAM-1) can guide the homing of various immune cells to the proper anatomical location within secondary lymphoid organs (SLOs), which are the major niches for generating immune responses or tolerance. MSCs rarely migrate to SLOs after intravenous infusion, and are constitutively low expression of ICAM-1. So in our previous work, ICAM-1 was engineered into a murine MSC line C3H10T1/2 by retrovirus transfection system (ICAM-1MSCs). Here, we hypothesized that ICAM-1 
Introduction
Acute graft-versus-host disease (GVHD) is a major obstacle following allogeneic hematopoietic stem-cell transplantation (HSCT) [1] , which is caused by alloreactive T cells that recognize alloantigens initially presented by host/donor antigen-presenting cells (APCs) [2] [3] [4] . Although GVHD can sometimes be constrained with rigorously T cell-depleted donor grafts or pharmacologic agents, such treatments predispose patients to relapses in malignancy and opportunistic infections. Mesenchymal stem cells (MSCs) are a heterogeneous population of plastic-adherent cells with the capacity to differentiate in vitro into osteoblasts, adipocytes and chondroblasts, which have a wide range of immunosuppressive effects on innate and adaptive immune cells [5, 6] . Nearly all immune cells, including T, B, natural killer (NK), and dendritic cells (DCs), are affected. Because of their relatively convenient isolation, ex vivo expansion, and low toxicity, the clinical utility of MSCs has rapidly expanded in recent years.
However, the immunosuppressive capacity of MSCs is not always as effective as originally hypothesized. Some researchers have claimed that MSCs have a protective effect against GVHD [7] . This effect has not been observed consistently in mouse models [8] . In addition, the results of clinical trials with MSCs are also confusing, as earlier trials showed substantial benefits, whereas two recent multicenter, prospective phase III trials with at least one source of MSCs did not show any benefit [9, 10] . Currently, it is recognized that the inefficient homing of systemically infused MSCs is a major barrier of existing MSC-based clinical GVHD therapy [11, 12] .
Intercellular adhesion molecule-1 (ICAM-1) is a highly glycosylated protein that belongs to the immunoglobulin superfamily of cell adhesion molecules (CAMs), which were reported to play crucial roles in the specific and effective immune response to foreign pathogens [13, 14] . ICAM-1 is normally constitutively expressed on the surface of a wide variety of cell types, including leukocytes, endothelial cells, and fibroblasts [15] . It can guide the homing of various immune cells to the proper anatomical location within secondary lymphoid organs (SLOs). Normally, MSCs constitutively express a low level of ICAM-1 [16] [17] [18] . In our previous work, a recombinant retrovirus vector containing the mouse ICAM-1 gene was successful constructed [19] . The overexpressing-ICAM-1 HIGH MSCS cell line (ICAM-1MSCs) was obtained by the transfection of the MSC cell line C3H10T 1/2. Forced expression of ICAM-1 almost did not alter the immunophenotype. ICAM-1 high MSCs are positive for CD29, CD44, and Sac-1 and are negative for CD45, CD11b, CD31 and CD86. As for the multilineage differentiation potential, ICAM-1 high MSCs have the capacity to differentiate in vitro into osteoblasts, adipocytes and chondroblasts. Although other researchers have demonstrated that increased ICAM-1 is critical for MSC-mediated immunosuppression, the role of ICAM-1 in preventing GVHD has not been widely studied.
In this article, we show that overexpression of ICAM-1 enhances the immunomodulatory activity of MSCs and that they interact with DCs or T cells by making MSCs more adhesive to cells, which plays an important role in MSC-mediated immunosuppression. Therefore, this article uncovers a novel role of adhesion molecules in preventing GVHD in a mouse model, which will provide a potential future approach for the prevention or treatment of GVHD in patients.
Materials and Methods
Mice Female C57BL/6 (B6, H2b) and BALB/c (BALB/c, H-2d) mice were purchased from Vital River (Charles River China). The age of the mice ranged from 8 to 10 weeks. All mice were kept under specific pathogen-free conditions and utilized in the animal center of the Academy of Military Medical Sciences. All experiments in this study were performed in accordance with the Academy of Military Medical Sciences Guide for Laboratory Animals (IACUC of AMMS-2013-021). 
Cell preparations
Bone marrow cells (BMCs) were collected from the backbones and femurs. The spleens were crushed through 40-μm screens, and then, cell suspensions were prepared by centrifugation with a Ficoll gradient at 1000x g for 20 min to separate leukocytes from the cell debris. The leukocytes were collected from the interface and washed before use. Primary MSCs (pMSCs) were isolated from newborn C57BL/6 murine compact bone and culture-expanded in α-minimal essential medium (α-MEM, Gibco) containing 10% fetal bovine serum in a humidified atmosphere of 5% CO 2 at 37℃. The murine MSC line C3H10T1/2 (CCL-226) was obtained from ATCC. MSCs/MSCV (C3H10T1/2 cells transfected with the empty vector), and ICAM-1 MSCs were obtained as described in our previous report and passaged and expanded in MSC culture medium.
Preparation of DCs from bone marrow cells and DCs co-culture with MSCs in vitro.
BMCs from mouse (8 weeks old) femur were prepared by the depletion of red cells and were then cultured at a density of 2×10 6 cells/ml in 6-well plates in minimal essential medium (MEM, Gibco, Grand Island) with 10% fetal bovine serum (FBS), 10 ng/ml of recombinant mouse granulocyte-monocyte colonystimulating factor (mGM-CSF, RD) and 1 ng/ml of recombinant mouse IL-4 (mIL-4, RD). On day 4, DCs were collected and co-cultured with pMSCs, MSCs/MSCV, or ICAM-1 MSCs at a ratio of 5:1 for 3 additional days in the presence of 1 μg/ml LPS with the intent of stimulating DCs maturation. At day 7, the cell morphology of the DCs and MSCs co-cultured DCs was observed under the microscope (Nikon TE2000-U), and the DCs were collected and CD11c, CD80, CD86 and Ia were used as indicators of fully mature DCs by flow cytometry.
Mixed lymphocyte response (MLR) and lymphoblast transformation test (LTT)
As for MLR testing, MSCs or ICAM-1 MSCs were preplaced in 96-well plates at 1×10 /well) and irradiated 24 hours later at 15 Gy. Splenic T lymphocytes from BALB/c mice were added to the coculture with MSCs at a density of 2×10 5 /well in 96-well plates. Concanavalin A (5 mg/ml) (ConA; Sigma Aldrich Co.) were added to promote mitogen proliferation, and a negative control well contained only splenocytes from BALB/c mice. The plates were maintained at 37℃ for 56 hours and then pulsed with 1 mCi of 3 H thymidine deoxyribonucleoside per milliliter for another 16 hours. The cells were then harvested onto glass fiber filters, and their radioactivity was measured on a Wallac Microbeta Trilux 1450-02P. All experiments were performed in triplicate and repeated three times.
Murine GVHD Model
Mice underwent transplantation according to following protocol. Briefly, the recipients received a single dose of 800 cGy total body irradiation (TBI, Co 60 γ source). In the GVHD group, BMCs (10×10 6 ) and Spleen mononuclear cells (SPMNC) ( 10×10 6 ) from C57BL/6 mice were suspended in a total volume of 0.2 ml of PBS and injected intravenously into recipient animals on day 0. pMSCs (5×10 ) were injected into GVHD mice 24 hours after transplantation. The body weights and survival were monitored daily, and the GVHD clinical scores were measured weekly. The degree of systemic acute GVHD was assessed using a scoring system that incorporates five clinical parameters: weight loss, posture (hunching), activity, fur texture and skin integrity. Histopathology of GVHD was monitored according to Kaplan et al. [20] . Specimens from at least three recipient mice per group were collected for experiments except where otherwise described.
In vivo tracking of exogenously infused MSCs
To track MSCs in the GVHD models, MSCs (5×10 Immune factor determination by real-time PCR and ELISA RNase-free plastic and water were used throughout the assay. Total RNA was extracted with TRIzol reagent (Invitrogen) and reverse transcribed using the RevertAid First Strand cDNA Synthesis Kit (Thermo). cDNAs were amplified by qRT-PCR using a SYBR Green PCR kit (Sigma). The qRT-PCR results were normalized using mouse HPRT as the housekeeping gene. All cDNA sequences were obtained from the GenBank database. The primer sequences used for the qRT-PCR are listed in Table 1 . Meanwhile, Mouse IFN-γand IL-10 concentrations were determined according to the reagent protocols of the quantitative determination kit (eBioscience).
Flow cytometry analysis
Antibodies, including PE-CY5 anti-mouse CD11c, PE anti-mouse CD86, FITC anti-mouse CD80, PE anti-mouse CDIA, FITC anti-mouse H2Kb, APC/Cy7 anti-mouse CD3, PerCP/Cy5.5 anti-mouse CD8, PE antimouse IFN-gamma, PE anti-mouse IL4, and PE/Cy7 anti-mouse IL17A, were purchased from Biolegend. The procedure was performed as described elsewhere. Briefly, for surface staining, approximately one million cells were incubated with saturating concentrations of the antibody mixture at 4 ℃ for 30 minutes as illustrated in the instructions. For intracellular cytokine analysis, leukocytes isolated from spleen cells were stimulated with a Cell Stimulation Cocktail with protein transport inhibitors (500×, eBioscience), which could be directly added to the culture medium at 1X (2 μL/mL), for 4-18 h. For intracellular cytokine staining, cells were fixed and permeabilized using the BD IntraSure Kit.
Statistical analysis
The Kaplan-Meier product-limit method was used to calculate the survival curve. Differences between groups in the survival studies were determined using log-rank statistics. For all other data, Student's t test was used to analyze differences between groups, and the results were considered significant if the p value was less than or equal to 0.05. Unless otherwise specified, all error bars in this study are the S.E.M.
Results

Overexpressing ICAM-1 enhanced the suppression capacity of MSCs for DCs in vitro
DCs are specialized antigen-presenting cells that are pivotal in immune responses. It is generally accepted that immature DCs (iDC) in the periphery become mature and migrate to secondary lymphoid organs, where T cells are activated [21] . To investigate the enhanced expression of ICAM-1 on MSCs in the determination of DC fate, first, we found that numerous mature DCs (maDC) were generated from BMC using mIL4/mGM-CSF supplemented with an additional LPS incubation (Fig. 1 B) . In terms of the cellular morphology, maDC were found to be relatively disperse and had long synapses (Fig. 1 A) . After 3 days of co-culture with MSCs, numerous DCs were adhered to MSCs, and the long synapses could not be seen under a microscope, especially for ICAM-1 MSCs (Fig. 1A) . Surface expression of costimulatory reverse, 5′-GCTGGTGAAAAGGACCTCTCG -3′
forward, 5′-CACTTGGTGGTTTGCTACGA-3′
reverse, 5′-GCCTCCCTCTCATCAGTTCTA-3′
forward, 5′-ACTCCATGCTTGAAGAAGAACTC -3′
reverse, 5′-ATGATGCTCTTTAGGCTTTCCA -3′
forward, 5′-TTACTACCTTCTTCAGCAACAGCAA -3′
reverse, 5′-CTGGTGGACCACTCGGATGA -3′
forward, 5′-AGAGCCCTCACAACCAGCTA -3′
reverse, 5′-CCAGATGTTGTGGGTGAGTG -3′ (Fig. 1B) . of pMSCs reduce mortality to 20% (Fig.  3A) , while ICAM-1 MSCs infusion could rescue mortality to approximately 50% (Fig. 3A) . The lowest GVHD scores were detected with the infusion of 5×10 5 ICAM-1 MSCs (Fig. 3B) Fig. 4 ). (Fig. 6 ). Treg are defined by their expression of CD4, CD25 and the transcription factor forkhead box P3 (FOXP3), and control innate and adaptive immune responses [22] . Among these group, Treg cell skewing in ICAM-1MSC-treated mice was also observed (Fig. 6 ).
Overexpressing ICAM-1 enhanced the immunosuppression capacity of MSCs for DCs in vivo
Since ICAM-1 MSCs gained an immunosuppression capacity for DCs in vitro, we further examined whether they could suppress DCs function in the spleen after intravenous infusion. Seven days after infusion, surface expression of CD11c was
Enhanced expression of ICAM-1 affected the expression of T cell related cytokine
Th1 type cytokine, such as IFN-γ and TNFα have been shown to be aetiological factors in the induction of GVHD [23] . Th2-type cytokines, such as IL-4, can reduce acute GVHD [24] . The mRNA levels of the Th1 cytokines IFN-γ and TNFα were strongly decreased in mice co- transplanted with ICAM-1 MSCs (Fig. 7A and 7B ), while the expression of IL4 displayed no obvious change among each group (Fig. 7C ). Most importantly, Treg cell skewing in ICAM-1MSC-treated mice was also observed, and mRNA expression of foxp3 was also up-regulated (Fig. 7D) . Th1 serum cytokine concentration of IFN-γ obviously decreased in the group treated with ICAM-1 MSCs (Fig. 7E) , while Treg related serum cytokine concentration of IL10 was elevated in mice treated with ICAM-1 high MSCs compared to GVHD group (Fig. 7F) .
Discussion
GVHD presents a major complication after allogeneic bone marrow transplantation. Idiopathic pneumonia syndrome (IPS) may be considered as a pulmonary manifestation of GVHD. The immunosuppressive properties of MSCs have been established, and the treatment of GVHD/IPS with MSCs has been reported, which suggests that MSCs can inhibit undesirable immune responses [25, 26] . Recently, several clinical trials using MSCs infusions have been reported. However, these reports were confusing, as they did not show any benefit after MSCs infusion [27] . The experimental basis of MSCs is somewhat limiting the clinical use of MSCs. MSCs do not readily migrate into the appropriate target tissues, and this creates a major obstacle for the use of MSCs.
Some methods have been developed to enhance the migration of MSCs to target organs. Attaching a synthetic high affinity peptidomimetic ligand (LLP2A) to integrin α4β1 on the MSCs surface can direct MSCs to the designated sites [28] . The high expression of CXCR4 enhanced the homing and engraftment of MSCs by increasing the response to SDF-1 [29, 30] . Additionally, CCR7 overexpression enhanced the homing of MSCs to secondary lymphoid organs and thus high ly intensified their in vivo immunomodulatory effect [31] . To our knowledge, we show for the first time, that the positive therapeutic effects of ICAM-1 MSCs in GVHD animal models with improved survival, low GVHD scores and attenuated tissue injury. Of note, transplanted ICAM-1 high MSCs enhanced their homing to SLOs in vivo. SLOs are also a strategically positioned collecting station for initiating the adaptive immune response, where a naive T cell scan the surfaces of antigen-presenting cells for cognate antigens and activates and generates armed effectors under the signaling cues from the APC [32] [33] [34] [35] . And it was also found that in the absence of secondary stimulation even high numbers of host-reactive T cells are hardly activated in GVHD [36] . The fate of the murine GVHD model is determined at least partially by the types and numbers of effector T cells. It is generally understood that Th1 cells and pro-inflammatory molecules such as IFN-γ and TNFα have been shown to be aetiological factors in the induction of GVHD [37, 38] . These pro-inflammatory molecules contribute to a systemic syndrome with variable presentations of weight loss, diarrhea and skin changes, and increased mortality. ICAM-1 high MSCs infusion reduced the percentage of Th1, and the expression of IFN-γ and TNFα. The presence of Treg cells was recognized as one of the critical factors in attenuating GVHD. Natural Treg cells, which are defined by their expression of CD4, CD25 and FOXP3, regulate innate and adaptive immune response [39, 40] . Treg cell impairment is associated with a loss of tolerance, as well as with GVHD [41] . So Several papers have shown that MSCs suppress T-cell immunity in vitro by both direct cell-cell contact and the soluble substances that MSCs release in the supernatants [42] [43] [44] . Our results here showed that ICAM-1 MSCs could suppress DC differentiation to maDCs, and suppress the T cell immune response as shown by the MLR and LTT tests in vitro. Additionally, when DCs were co-cultured with MSCs-conditioned medium in vitro, we observed that the ICAM-1 high MSCs supernatant had a greater inhibition efficiency for DCs compared with other groups (unpublished data), which clearly indicates that such an effect not only depends on the physical contact between MSCs and DCs, but also on soluble factors released by ICAM1MSCs. These soluble factors maybe not constitutively secreted by MSCs. It is important to further explore which molecules secreted by ICAM-1 MSCs plays a crucial role in immune regulation.
Conclusion
Taken together, our results indicate that ICAM-1 high MSCs had greater migration activity to the modulatory center (SLOs) of immune responses in a mouse model. Given that MSCs express a low level of ICAM-1, it is plausible to speculate that a novel strategy could be applied to human MSCs to achieve targeted organ trafficking to attenuate GVHD.
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